Orchid Cellmark's Q4 Revenues Rise 21 Percent on Forensics Testing Services

Orchid also turned a profit for the quarter, as it recognized license fees from a deal with Illumina.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories